ATG2B and metabolic dysfunction-associated steatohepatitis: The advantage of this study is that Rg1 is a monomer for NASH therapy, and the results also suggest that Rg1 can improve the progression of NASH in vitro via miR-375-3p/ATG2B/PTEN-AKT.